Nuvation Bio (NUVB) Stock Price, News & Analysis

Company Overview

Nuvation Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for the treatment of cancer. The company uses small-molecule drug discovery and development approaches to pursue therapies intended to address difficult-to-treat tumors and areas of significant unmet medical need.

Nuvation Bio’s pipeline has included NUV-868, an oral investigational inhibitor of DYRK1A being studied in solid tumors, and NUV-1511, an investigational oncology drug designed to interfere with cancer-cell DNA damage response mechanisms. The company has also expanded its development capabilities through the acquisition of AnHeart Therapeutics, adding radiopharmaceutical research and development programs to its broader oncology portfolio.

Nuvation Bio was founded by David Hung, M.D., who serves as the company’s founder, president and chief executive officer. The company became a publicly traded business in 2021 and is headquartered in the United States, where it conducts its research and development activities in collaboration with clinical and scientific partners.

Key Stats

• Today's Range: $4.85 to $5.16
• 50-Day Range: $5.12 to $7.25
• 52-Week Range: $3.36 to $9.75
• Volume: 9.96 million shs
• Average Volume: 5.53 million shs
• Market Capitalization: $1.74 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.22
• Consensus Rating: Moderate Buy

Nuvation Bio Stock Analysis - MarketRank™

Nuvation Bio scored higher than 55% of companies evaluated by MarketBeat, and ranked 433rd out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Nuvation Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 9 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Nuvation Bio has a consensus price target of $13.22, representing about 164.2% upside from its current price of $5.01.

Amount of Analyst Coverage

Nuvation Bio has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Nuvation Bio are expected to grow in the coming year, from ($0.34) to ($0.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nuvation Bio is -11.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nuvation Bio is -11.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nuvation Bio has a P/B Ratio of 5.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

23.71% of the float of Nuvation Bio has been sold short.

Short Interest Ratio / Days to Cover

Nuvation Bio has a short interest ratio ("days to cover") of 10.89, which indicates bearish sentiment.

Change versus previous month

Short interest in Nuvation Bio has recently increased by 7.20%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nuvation Bio does not currently pay a dividend.

Dividend Growth

Nuvation Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.34

News Sentiment

Nuvation Bio has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Nuvation Bio this week, compared to 6 articles on an average week.

Search Interest

Only 14 people have searched for NUVB on MarketBeat in the last 30 days. This is a decrease of -26% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Nuvation Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Nuvation Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $709,000.00 in company stock.

Percentage Held by Insiders

30.11% of the stock of Nuvation Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

61.67% of the stock of Nuvation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/05/2026
• Next Earnings (Estimated): 11/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSE:NUVB
• CIK: 1811063
• Web: www.nuvationbio.com
• Phone: 332-208-6102
• Fax: N/A
• Employees: 305
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Nuvation Bio: $13.22
• High Price Target: $21.00
• Low Price Target: $7.00
• Potential Upside/Downside: +166.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.44)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$204.63 million
• Net Margins: -88.18%
• Pretax Margin: -88.18%
• Return on Equity: -46.59%
• Return on Assets: -22.01%

Debt

• Debt-to-Equity Ratio: 0.96
• Current Ratio: 8.37
• Quick Ratio: 8.14

Sales & Book Value

• Annual Sales: $62.90 million
• Price / Sales: 27.72
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.88 per share
• Price / Book: 5.64

Miscellaneous

• Outstanding Shares: 351,120,000
• Free Float: 245,400,000
• Market Cap: $1.74 billion
• Optionable: Optionable
• Beta: 1.61